What is the optimal first-line regimen for patients with advanced HER2-positive breast cancer: A systematic review and network meta-analysis
{{output}}
Background: The advent of anti-HER2 agents, such as trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1), has significantly improved survival in metastatic HER2-positive breast cancer (BC). Multiple anti-HER2 combination re... ...
